Vanguard Group’s Monte Rosa Therapeutics GLUE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $14.2M | Buy |
3,140,510
+40,474
| +1% | +$183K | ﹤0.01% | 2723 |
|
|
2025
Q1 | $14.4M | Sell |
3,100,036
-56,318
| -2% | -$261K | ﹤0.01% | 2653 |
|
|
2024
Q4 | $21.9M | Buy |
3,156,354
+622,134
| +25% | +$4.32M | ﹤0.01% | 2542 |
|
|
2024
Q3 | $13.4M | Sell |
2,534,220
-12,855
| -0.5% | -$68.1K | ﹤0.01% | 2807 |
|
|
2024
Q2 | $9.53M | Buy |
2,547,075
+911,246
| +56% | +$3.41M | ﹤0.01% | 2958 |
|
|
2024
Q1 | $11.5M | Buy |
1,635,829
+47,412
| +3% | +$334K | ﹤0.01% | 2871 |
|
|
2023
Q4 | $8.97M | Sell |
1,588,417
-39,960
| -2% | -$226K | ﹤0.01% | 3010 |
|
|
2023
Q3 | $7.8M | Buy |
1,628,377
+71,589
| +5% | +$343K | ﹤0.01% | 3031 |
|
|
2023
Q2 | $10.7M | Buy |
1,556,788
+109,354
| +8% | +$749K | ﹤0.01% | 2912 |
|
|
2023
Q1 | $11.3M | Buy |
1,447,434
+20,720
| +1% | +$161K | ﹤0.01% | 2873 |
|
|
2022
Q4 | $10.9M | Buy |
1,426,714
+19,047
| +1% | +$145K | ﹤0.01% | 2919 |
|
|
2022
Q3 | $11.5M | Sell |
1,407,667
-855,239
| -38% | -$6.99M | ﹤0.01% | 2883 |
|
|
2022
Q2 | $21.9M | Sell |
2,262,906
-739,866
| -25% | -$7.15M | ﹤0.01% | 2594 |
|
|
2022
Q1 | $42.1M | Buy |
3,002,772
+1,922,156
| +178% | +$26.9M | ﹤0.01% | 2391 |
|
|
2021
Q4 | $22.1M | Buy |
1,080,616
+60,595
| +6% | +$1.24M | ﹤0.01% | 2783 |
|
|
2021
Q3 | $22.7M | Buy |
1,020,021
+920,021
| +920% | +$20.5M | ﹤0.01% | 2796 |
|
|
2021
Q2 | $2.27M | Buy |
+100,000
| New | +$2.27M | ﹤0.01% | 3936 |
|